Suppr超能文献

基因代理抗糖尿病药物靶点与原发性开角型青光眼:一项孟德尔随机化研究

Genetically Proxied Antidiabetic Drug Target and Primary Open-Angle Glaucoma: A Mendelian Randomization Study.

作者信息

Tang Kefu, Wang Wenqiu, Chang Weiteng, Wu Xi

机构信息

Department of Clinical Laboratory, Prenatal Diagnosis Center, Changning Maternity and Infant Health Hospital East China Normal University Shanghai China.

Department of Ophthalmology, Shanghai General Hospital Shanghai Jiao Tong University School of Medicine Shanghai China.

出版信息

Health Sci Rep. 2024 Oct 24;7(10):e70162. doi: 10.1002/hsr2.70162. eCollection 2024 Oct.

Abstract

BACKGROUND AND AIMS

Observational studies suggest that antidiabetic drugs may lower POAG risk; while the causal relationship remains unclear. Naturally occurring variation in genes encoding antidiabetics drug targets can be used as proxies to investigate long-term therapeutic effect of these drugs on POAG risk.

METHODS

We performed a two-sample Mendelian randomization study to evaluate the potential effect of antidiabetic drug targets on POAG in Europeans and East Asians. To proxy antidiabetic drugs (ABCC8, PPARG, GLP1R, SLC5A2), we leveraged genetic variants located near or within drug target genes that were associated with HbA1c. The validity of our ancestry-specific genetic instrument was checked with multipul positive control outcomes. Genetic summary statistics of POAG from the International Glaucoma Genetics Consortium, Global Biobank Meta-analysis Initiative, and FinnGen consortia were analyzed for Europeans (38,164 cases and 1,576,179 controls) and East Asians (16,650 cases and 288,833 controls) separately. Inverse-variance weighted random-effects models were used as primary method.

RESULTS

MR results provided consistent evidence of a protective effect of ABCC8 inhibition on POAG using data sets from IGG, GBMI, and FinnGen. Genetically predicted one-standard deviation reduction in HbA1c from ABCC8 inhibition were significant associated with lower risk of POAG in Europeans (OR = 0.211, 95% CI: 0.133-0.333;  < 0.001) and East Asians (OR = 0.070, 95% CI: 0.011-0.459;  = 0.0056). The association between genetically predicted ABCC8 inhibition and risk of POAG was mainly mediated through intraocular pressure. No association was found for PPARG, SLC5A2, or GLP1R. Sensitivity analyses supported this observation.

CONCLUSIONS

We found a protective effect of genetically proxied ABCC8 inhibition on POAG risk in both Europeans and East Asians, highlighting ABCC8 as a promising candidate drug target for POAG, and mechanisms underlying the protective effect should also be investigated.

摘要

背景与目的

观察性研究表明抗糖尿病药物可能降低原发性开角型青光眼(POAG)风险;但其因果关系仍不明确。编码抗糖尿病药物靶点的基因中的自然发生变异可作为替代指标,用于研究这些药物对POAG风险的长期治疗效果。

方法

我们进行了一项两样本孟德尔随机化研究,以评估抗糖尿病药物靶点对欧洲人和东亚人POAG的潜在影响。为了替代抗糖尿病药物(ABCC8、PPARG、GLP1R、SLC5A2),我们利用了位于药物靶点基因附近或内部且与糖化血红蛋白(HbA1c)相关的基因变异。我们使用多个阳性对照结果检查了我们特定血统的基因工具的有效性。分别分析了来自国际青光眼遗传学联盟、全球生物样本库荟萃分析倡议组织和芬兰基因联盟的欧洲人(38164例病例和1576179例对照)和东亚人(16650例病例和288833例对照)的POAG基因汇总统计数据。采用逆方差加权随机效应模型作为主要方法。

结果

孟德尔随机化结果提供了一致的证据,表明使用来自国际青光眼遗传学联盟、全球生物样本库荟萃分析倡议组织和芬兰基因联盟的数据集,ABCC8抑制对POAG具有保护作用。在欧洲人中,通过ABCC8抑制使HbA1c遗传预测降低一个标准差与POAG风险降低显著相关(比值比[OR]=0.211,95%置信区间[CI]:0.133 - 0.333;P<0.001),在东亚人中(OR=0.070,95%CI:0.011 - 0.459;P=0.0056)。遗传预测的ABCC8抑制与POAG风险之间的关联主要通过眼压介导。未发现PPARG、SLC5A2或GLP1R存在关联。敏感性分析支持这一观察结果。

结论

我们发现基因替代的ABCC8抑制对欧洲人和东亚人的POAG风险均具有保护作用,突出了ABCC8作为POAG一个有前景的候选药物靶点,同时也应研究其保护作用的潜在机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74af/11499708/4ab0704bfb70/HSR2-7-e70162-g003.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验